Terumo (OTCMKTS:TRUMY) Sees Large Volume Increase – Should You Buy?

Terumo Corp. (OTCMKTS:TRUMY) shares saw strong trading volume on Monday. 881,418 shares changed hands during trading, an increase of 262% from the previous session’s volume of 243,282 shares. The stock last traded at $15.3630 and had previously closed at $15.19.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TRUMY shares. Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Terumo Stock Up 1.2%

The firm’s 50 day simple moving average is $14.96 and its 200-day simple moving average is $14.30. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $22.67 billion, a price-to-earnings ratio of 21.65 and a beta of 0.77.

Terumo (OTCMKTS:TRUMY) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. Equities analysts expect that Terumo Corp. will post 0.86 earnings per share for the current fiscal year.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.

The company’s products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.